ESR1 and breast carcinoma: In clinical practice, tamoxifen is one of the first-line endocrine therapies that competes with estrogen for ER and counteracts the estrogen signal pathway, which retards breast cancer growth (Swaby, Sharma & Jordan, 2007; Ye et al., 2019).